Results 241 to 250 of about 129,361 (307)

IgG Glycosylation‐Dependent CLEC7A Signaling Drives Podocyte Dysfunction in Lupus Nephritis

open access: yesArthritis &Rheumatology, Accepted Article.
Background Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE) that can lead to end‐stage kidney disease and increased mortality. Immunoglobulin G (IgG) from LN patients displays abnormal glycosylation, contributing to podocyte injury.
Rohit Upadhyay   +3 more
wiley   +1 more source

Developing a critical caste analysis within information science and technology: A research review: An annual review of information science and technology paper

open access: yesJournal of the Association for Information Science and Technology, EarlyView.
Abstract Caste—an ascriptive social hierarchy in South Asia and its diaspora—is a globalized phenomenon. Recent caste‐based discrimination, particularly in technology companies and anti‐caste efforts to address it, has compelled academia, policy, and the technology industry to better understand contemporary mechanics of caste.
Nayana Kirasur, Britt Paris
wiley   +1 more source

Determinants of Second Dose Measles Vaccination Coverage in Somaliland: A Binary and Multivariate Logistic Regression Analysis. [PDF]

open access: yesPublic Health Chall
Ali LH   +8 more
europepmc   +1 more source

Quality indicators for safe and effective medication use in long‐term care facilities: A modified Delphi study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim This modified Delphi study aimed to achieve expert agreement on quality indicators (QIs) suitable for application at the population level, to evaluate quality use of medications and pharmacist services in long‐term care facilities (LTCFs). Methods We conducted a two‐round modified online Delphi study with a multidisciplinary panel of Australian ...
Daria S. Gutteridge   +10 more
wiley   +1 more source

An age-structured spatially varying coefficient model for high-resolution mapping of vaccination coverage. [PDF]

open access: yesPLoS Comput Biol
Utazi CE   +5 more
europepmc   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar   +6 more
wiley   +1 more source

Influenza Vaccination Coverage Among Nursing Home Residents and Health Care Personnel - United States, 2024-25 Influenza Season. [PDF]

open access: yesMMWR Morb Mortal Wkly Rep
Bell JM   +14 more
europepmc   +1 more source

Oseltamivir drug‐disease modelling in infants with influenza virus infection

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Oseltamivir is a commonly used neuraminidase inhibitor for treatment of influenza infection, but little data exist regarding concentration‐response relationships. Methods Pharmacokinetic (PK) and viral dynamic data from an earlier NIAID Collaborative Antiviral Study Group trial in paediatric patients with influenza from 0–23 months of age
Kun Wang   +4 more
wiley   +1 more source

Do consumers and healthcare professionals report the same adverse event differently? A paired analysis of duplicate vaccine safety reports in Norway

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim This study aimed to compare how Norwegian healthcare professionals (HCPs) and consumers reported the same adverse event (AE) following immunization with vaccines against COVID‐19 during the COVID‐19 pandemic. Specifically, we aimed to compare the extent to which HCPs and consumers reported information relevant for assessing the causal relationship ...
Tommy Emil Dzus   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy